Alliqua major shareholder Celgene Corporation (NASDAQ:CELG) bought 714,286 shares of the company’s stock in a transaction that occurred on Monday, April 14th. The stock was purchased at an average cost of $7.00 per share, with a total value of $5,000,002.00. Celgene Corporation (NASDAQ:CELG) shares after opening at $148.09 moved to $148.09 on last trade day and at the end of the day closed at $144.82 . Company price to sales ratio in past twelve months was calculated as 9.05and price to cash ratio as 10.34. Celgene Corporation (NASDAQ:CELG) showed a positive weekly performance of 3.56%.
Inovio Pharmaceuticals Inc (NYSE:INO) CEO Jong Joseph Kim purchased 25,000 shares of the stock in a transaction dated Tuesday, April 15th. The stock was purchased at an average cost of $2.25 per share, for a total transaction of $56,250.00. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares fell -1.51% in last trading session and ended the day on $2.61 . INO return on equity ratio is recorded as -144.40% and its return on assets is -92.70%. Inovio Pharmaceuticals Inc (NYSEMKT:INO) yearly performance is 366.07%.
Opko Health Inc (NYSE:OPK) CEO Phillip Md Et Al Frost bought 89,500 shares of the stock in a transaction dated Tuesday, April 22nd. The shares were purchased at an average price of $8.29 per share, for a total transaction of $741,955.00. Opko Health Inc. (NYSE:OPK) shares moved down -1.81% in last trading session and was closed at $8.16 while trading in range of $8.10 – $8.33 – Opko Health Inc. (NYSE:OPK) year to date (YTD) performance is -3.32%.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Director Bruce Kovner bought 1,250,000 shares of Synta Pharmaceuticals Corp. stock on the open market in a transaction dated Friday, April 11th. The shares were purchased at an average price of $4.01 per share, for a total transaction of $5,012,500.00. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) weekly performance is 2.44%. On last trading day company shares ended up $4.19. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) distance from 50-day simple moving average (SMA50) is -18.03%. Analysts mean target price for the company is $13.83.
Leave a Reply